Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Schorlemmer
H U
HU
Research Laboratories, Hoechst Marion Roussel Deutschland GmbH, DG Rheumatology, Frankfurt, Germany. hansulrich.schorlemmer@hmrag.com
Milbert
U
U
Zeitter
D
D
Haun
G
G
Wunschel
M
M
Bartlett
R R
RR
D000814:Aniline Compounds / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects*; D003437:Crotonates; D000090722:Dihydroorotate Dehydrogenase; D006801:Humans; D006885:Hydroxybutyrates / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology*; D019169:Jurkat Cells; D000077339:Leflunomide; D009570:Nitriles; D010088:Oxidoreductases / Q000378:metabolism; D044925:Oxidoreductases Acting on CH-CH Group Donors; D011743:Pyrimidines / Q000096:biosynthesis*; D014052:Toluidines
D000814:Aniline Compounds; D003437:Crotonates; D000090722:Dihydroorotate Dehydrogenase; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D011743:Pyrimidines; D014052:Toluidines; C527525:teriflunomide; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; D000077339:Leflunomide